Supplemental Figures S1-S6 from EPHA2 Blockade Overcomes Acquired Resistance to EGFR Kinase Inhibitors in Lung Cancer

Localization of EPHA2 in erlotinib resistant cells (S1); Validation of EPHA2 antibody specificity in patient tumor specimens (S2); EPHA2 kinase activity is required in maintaining cell viability of erlotinib resistant lung cancer (S3); Biochemical analysis of TKI-­�resistant tumors from EGFRL858R+T790MEphA2-­�/-­� and control mice (S4); Signaling analysis in EPHA2 knockdown cells by siRNA-­�mediated gene silencing (S5); Localization of EPHA2 upon ligand or EPHA2 inhibitor treatment (S6).